Bacteriophage

Armata Pharmaceuticals' Phase 1b/2a diSArm trial demonstrated that AP-SA02, a novel intravenous bacteriophage therapy, met all primary endpoints for safety, tolerability, and clinical response in complicated Staphylococcus aureus bacteremia.

Researchers are exploring bacteriophages, viruses that infect and kill bacteria, as a potential solution to combat antimicrobial resistance (AMR), a growing global health threat. With the discovery of a bacteriophage in Merri Creek, Melbourne, capable of eliminating resistant Klebsiella pneumoniae, and ongoing clinical trials worldwide, phage therapy is emerging as a promising tool in the fight against superbugs.

A Hungarian research team has created a detailed global map of _Acinetobacter baumannii_, a dangerous hospital-acquired superbacterium, published in _Cell_.